- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches Physician-Led Patient Masterclass Program Following Grassroots Demand in the Southeast | 519 | ACCESS Newswire | After training more than 600 physicians in under a year, the biologics research and products company now turns its focus to assisting physicians in educating their patients on the science of regenerative... ► Artikel lesen | |
| 12.05. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 12.05. | Zeo ScientifiX, Inc.: ZEO ScientifiX Announces That Unaudited Monthly Sales Surpassed $1.0 million in April 2026, the First Time The Company Has Achieved This Milestone. | 180 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / May 12, 2026 / ZEO ScientifiX (OTCQB:ZEOX) ("ZEO" or the "Company"), a regenerative medicine products company serving physician-run clinics across the United... ► Artikel lesen | |
| 21.04. | Zeo ScientifiX, Inc.: ZEO ScientifiX Surpasses 500 Physicians Trained in Regenerative Medicine Compliance; Monthly Masterclasses Average 70+ Clinicians | 188 | ACCESS Newswire | DAVIE, FL / ACCESS Newswire / April 21, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO ScientifiX"), a provider of industry-leading clinical education in regenerative medicine innovation, proudly announces... ► Artikel lesen | |
| 21.04. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.04. | Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics--Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX | 2 | CNW | ||
| 09.04. | Zeo ScientifiX, Inc.: Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics - Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX | 415 | ACCESS Newswire | Regen Therapy's 24,000-practitioner network will unlock a fully integrated care ecosystem - featuring Stealth Health's licensed prescriber team and specialized therapies, Metabolic Code-driven longevity... ► Artikel lesen | |
| ZEO SCIENTIFIX Aktie jetzt für 0€ handeln | |||||
| 07.04. | Zeo ScientifiX, Inc.: ZEO ScientifiX Selected as Qualified Team Advancing into the XPRIZE Healthspan Semi-Finals Stage | 428 | ACCESS Newswire | DAVIE, FL / ACCESS Newswire / April 7, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO" or the "Company"), a clinical-stage biotechnology company, today announced its selection as a Qualified Team advancing... ► Artikel lesen | |
| 07.04. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 29.01. | Zeo ScientifiX, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 21.01. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.01. | ZEO ScientifiX, Inc.: Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States | 349 | ACCESS Newswire | Three-Way Collaboration to Bring Innovative Oral Mucosal Stem Cell Therapy with U.S. GMP Manufacturing and Commercialization Infrastructure to Patients Seeking Treatment for Non-healing Diabetic Foot... ► Artikel lesen | |
| 05.01. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.10.25 | ZEO ScientifiX, Inc.: ZEO ScientifiX Positioned for New Growth as Florida Opens Stem Cell Market | 468 | ACCESS Newswire | New Florida stem cell law provides ZEO with new pathways to market and sell regenerative therapy products and advance clinical research initiatives FORT LAUDERDALE, FL / ACCESS Newswire / October 23... ► Artikel lesen | |
| 09.07.25 | Zeo ScientifiX, Inc.: ZEO ScientifiX Positions for National Growth as Stem Cell Market Opens in Florida | 643 | ACCESS Newswire | ZEO Launches New Website and Agency Partnerships to Address Expected Biologics Market Demand Following Florida's New Stem Cell Law FORT LAUDERDALE, FL / ACCESS Newswire / July 9, 2025 / ZEO ScientifiX... ► Artikel lesen | |
| 24.06.25 | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches Physician-Focused Masterclass Ahead of Florida's SB-1768 Law Implementation | 342 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / June 24, 2025 / ?ZEO ScientifiX, Inc.?("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company pioneering the research and development... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 254,00 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 35,590 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| JADE BIOSCIENCES | 16,940 | 0,00 % | Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy | ~70% IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a single subcutaneous maintenance injection every 12 weeksIgA-lowering effect... ► Artikel lesen | |
| QIAGEN | 31,920 | -2,18 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,86 | -0,07 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| ADMA BIOLOGICS | 7,970 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| SUMMIT THERAPEUTICS | 14,755 | -0,10 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 11,970 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,720 | +0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 59,28 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,520 | 0,00 % | Relay Therapeutics Shares Jump 18% | ||
| BEAM THERAPEUTICS | 29,370 | -0,10 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,190 | -0,15 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOCARDIA | 1,070 | +3,88 % | BioCardia Shares Surge 48% After FDA Feedback Supports Potential CardiAMP Approval Pathway |
Das Unternehmen ZEO SCIENTIFIX INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZEO SCIENTIFIX INC finden Sie auf Wallstreet Online.